For patients with type 2 diabetes (T2D) and chronic obstructive pulmonary disorder (COPD), sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor agonists (GLP-1 RAs ...

The FDA said the shortage of Novo Nordisk's weight-loss drugs Wegovy and Ozempic is resolved. The move could limit cheaper ...

Treatment for OUD is currently dominated by opioid agonist therapies that are highly regulated due to their liability for ...

Tirzepatide is just as effective in reducing cardiovascular risk driven by central adiposity as that driven by general ...

Weight loss injections have become incredibly popular in the last year or so. In fact, these medications are so widely used ...

Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s semaglutide (Ozempic, Wegovy) and Eli Lilly’s ...

Research shows bimagrumab may prevent muscle and bone loss associated with weight loss medications like Wegovy, offering hope ...

Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

RAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent results for mood disorders.

The federal health insurance program has selected 15 additional drugs covered by Medicare Part D for its next round of price ...

GLP-1) receptor agonists, which are used to treat type 2 diabetes and/or obesity, were linked to vision problems in a small study. Here's what doctors have to say.